JP6236077B2 - 持続時間が超短期、短期、または中期の非対称性逆転可能神経筋遮断物質 - Google Patents

持続時間が超短期、短期、または中期の非対称性逆転可能神経筋遮断物質 Download PDF

Info

Publication number
JP6236077B2
JP6236077B2 JP2015520604A JP2015520604A JP6236077B2 JP 6236077 B2 JP6236077 B2 JP 6236077B2 JP 2015520604 A JP2015520604 A JP 2015520604A JP 2015520604 A JP2015520604 A JP 2015520604A JP 6236077 B2 JP6236077 B2 JP 6236077B2
Authority
JP
Japan
Prior art keywords
neuromuscular blocking
cysteine
neuromuscular
group
blocking substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015520604A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015522033A5 (enExample
JP2015522033A (ja
Inventor
ジョン ジェイ． サバレーゼ
ジョン ジェイ． サバレーゼ
ジェフ ディー． マギルブラ
ジェフ ディー． マギルブラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of JP2015522033A publication Critical patent/JP2015522033A/ja
Publication of JP2015522033A5 publication Critical patent/JP2015522033A5/ja
Application granted granted Critical
Publication of JP6236077B2 publication Critical patent/JP6236077B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015520604A 2012-06-29 2013-06-28 持続時間が超短期、短期、または中期の非対称性逆転可能神経筋遮断物質 Active JP6236077B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261666244P 2012-06-29 2012-06-29
US61/666,244 2012-06-29
US201261703991P 2012-09-21 2012-09-21
US61/703,991 2012-09-21
US201361817706P 2013-04-30 2013-04-30
US61/817,706 2013-04-30
PCT/US2013/048771 WO2014005122A2 (en) 2012-06-29 2013-06-28 Asymmetrical reversible neuromuscular blocking agents of ultra-short, short, or intermediate duration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017207722A Division JP6709205B2 (ja) 2012-06-29 2017-10-27 持続時間が超短期、短期、または中期の非対称性逆転可能神経筋遮断物質

Publications (3)

Publication Number Publication Date
JP2015522033A JP2015522033A (ja) 2015-08-03
JP2015522033A5 JP2015522033A5 (enExample) 2016-08-18
JP6236077B2 true JP6236077B2 (ja) 2017-11-22

Family

ID=49784044

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015520604A Active JP6236077B2 (ja) 2012-06-29 2013-06-28 持続時間が超短期、短期、または中期の非対称性逆転可能神経筋遮断物質
JP2017207722A Active JP6709205B2 (ja) 2012-06-29 2017-10-27 持続時間が超短期、短期、または中期の非対称性逆転可能神経筋遮断物質
JP2020013449A Active JP7028474B2 (ja) 2012-06-29 2020-01-30 持続時間が超短期、短期、または中期の非対称性逆転可能神経筋遮断物質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017207722A Active JP6709205B2 (ja) 2012-06-29 2017-10-27 持続時間が超短期、短期、または中期の非対称性逆転可能神経筋遮断物質
JP2020013449A Active JP7028474B2 (ja) 2012-06-29 2020-01-30 持続時間が超短期、短期、または中期の非対称性逆転可能神経筋遮断物質

Country Status (5)

Country Link
US (1) US9156826B2 (enExample)
EP (1) EP2867219B1 (enExample)
JP (3) JP6236077B2 (enExample)
ES (1) ES2625329T3 (enExample)
WO (1) WO2014005122A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018048183A (ja) * 2012-06-29 2018-03-29 コーネル・ユニバーシティーＣｏｒｎｅｌｌ Ｕｎｉｖｅｒｓｉｔｙ 持続時間が超短期、短期、または中期の非対称性逆転可能神経筋遮断物質

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2167748B2 (en) † 2007-05-31 2015-03-25 Vestas Wind Systems A/S A system for damping oscillations in a structure
WO2016056581A1 (ja) 2014-10-08 2016-04-14 国立研究開発法人理化学研究所 植物成長促進剤及び植物成長促進方法
CN110776481B (zh) * 2018-07-24 2023-06-16 四川大学华西医院 一类双阳离子化合物及其制备方法和用途
TW202128628A (zh) * 2019-12-11 2021-08-01 大陸商江蘇恆瑞醫藥股份有限公司 神經肌肉阻滯劑及其製備方法
WO2022082051A1 (en) * 2020-10-17 2022-04-21 Cornell University Methods for controlling and predicting recovery after nmba administration
CN113092656B (zh) * 2021-02-22 2022-05-20 扬子江药业集团有限公司 一种注射用维库溴铵药物中有关物质的检测方法
CN120457118A (zh) * 2023-01-12 2025-08-08 海思科医药集团股份有限公司 一种双季铵盐化合物及其在医药上的应用
WO2025140279A1 (zh) * 2023-12-25 2025-07-03 上海森辉医药有限公司 季铵化合物及其药物用途
WO2025140288A1 (zh) * 2023-12-25 2025-07-03 上海森辉医药有限公司 一种四氢异喹啉及其药物用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8418303D0 (en) * 1984-07-18 1984-08-22 Wellcome Found Compounds
PE68399A1 (es) * 1997-03-25 1999-07-23 Cornell Res Foundation Inc Derivado de isoquinolina como bloqueador neuromuscular de accion ultra corta
GB0204087D0 (en) 2002-02-21 2002-04-10 Legislator 1563 Ltd Di-ester derivatives as short acting neuromuscular blockers
US20050192243A1 (en) * 2003-10-28 2005-09-01 Savarese John J. Neuromuscular blocking agents and antagonists thereof
ATE554769T1 (de) 2006-12-06 2012-05-15 Cornell Res Foundation Inc Neuromuskuläre blocker mit mittlerer dauer und antagonisten advon
AU2008264802A1 (en) 2007-06-18 2008-12-24 Chemagis Ltd. (1R,1'R)-atracurium salts separation process
WO2010107488A1 (en) 2009-03-17 2010-09-23 Cornell University Reversible nondepolarizing neuromuscular blockade agents and methods for their use
EP2867219B1 (en) * 2012-06-29 2017-02-15 Cornell University Asymmetrical reversible neuromuscular blocking agents of ultra-short, short, or intermediate duration

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018048183A (ja) * 2012-06-29 2018-03-29 コーネル・ユニバーシティーＣｏｒｎｅｌｌ Ｕｎｉｖｅｒｓｉｔｙ 持続時間が超短期、短期、または中期の非対称性逆転可能神経筋遮断物質

Also Published As

Publication number Publication date
JP6709205B2 (ja) 2020-06-10
ES2625329T3 (es) 2017-07-19
JP2020063305A (ja) 2020-04-23
EP2867219A2 (en) 2015-05-06
WO2014005122A3 (en) 2014-03-13
EP2867219A4 (en) 2015-11-25
US9156826B2 (en) 2015-10-13
JP2015522033A (ja) 2015-08-03
WO2014005122A2 (en) 2014-01-03
US20150191453A1 (en) 2015-07-09
JP7028474B2 (ja) 2022-03-02
EP2867219B1 (en) 2017-02-15
JP2018048183A (ja) 2018-03-29

Similar Documents

Publication Publication Date Title
JP7028474B2 (ja) 持続時間が超短期、短期、または中期の非対称性逆転可能神経筋遮断物質
CN103249697B (zh) 适用作多巴胺能稳定剂的普利多匹定(pridopidine)氘化类似物
JP6087367B2 (ja) 三環式化合物、それらを含む組成物およびそれらの使用
AU2020206826B2 (en) Ketamine pamoate and use thereof
CA2922340A1 (en) Ketamine derivatives
RU2007101653A (ru) Производные 1-азабицикло[3.3.1]нонанов
CN115160227A (zh) R-或s-2-(1-乙酰氧正戊基)苯甲酸与4-氟-依达拉奉的杂合物及其制备与应用
WO1999016431A1 (en) Mixtures of enantiomers of aminocyclohexylamides to produce simultaneous analgesia with local anaesthesia or antiarrhythmia
AU725577B2 (en) Smooth muscle spasmolytic agents, compositions and methods of use thereof
JP2024116269A (ja) 神経因性疼痛の治療におけるフェニルキノリノン系誘導体およびフラボノイド系誘導体の使用
KR102721799B1 (ko) 신규한 카나비디올 유도체, 이의 제조 방법 및 이를 포함하는 파킨슨병의 예방 또는 치료용 조성물
HUE024560T2 (hu) Pantenil-dokozahexanoát, valamint ennek alkalmazása szív-érrendszeri betegségek kezelésére és megelõzésére
CN101209994A (zh) 选择性m4受体拮抗剂及其医药用途
CN104211615B (zh) 苯基氟取代的苯乙酸酯化合物及其应用
SA109300406B1 (ar) ثينيل- وفيرانيل أيزوكوينولينونات وطرق لاستخدامها
JP2019509321A (ja) 疼痛を処置するための組み合わせ
CN120501745A (zh) 一种双氯芬酸罗哌卡因组合物及其制备方法
CN115960080A (zh) 一种多环化合物及其作为胃饥饿素受体激动剂的用途
BR112021013340B1 (pt) Sal de pamoato de cetamina e usos de uma composição farmacêutica compreendendo o referido sal
WO2020146878A1 (en) Salt and crystalline forms of rapastinel
RU2006117558A (ru) ЗАМЕЩЕННЫЕ 1,2,3,7-ТЕТРАГИДРОПИРРОЛО[3,2-f][1,3]БЕНЗОКСАЗИН-5-КАРБОНОВЫХ КИСЛОТ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
NZ619257B2 (en) Ketamine derivatives

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150526

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20160427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160628

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160628

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170522

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170929

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171027

R150 Certificate of patent or registration of utility model

Ref document number: 6236077

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250